Pardes Biosciences reported topline data from its Phase II clinical trial of pomotrelvir to treat mild to moderate Covid-19 in adult patients.
The randomised, double-blind Phase II clinical trial was designed for assessing the safety, clinical efficacy, and antiviral activity of pomotrelvir against a placebo.
According to the findings, pomotrelvir failed to meet the trial’s primary endpoint as measured by proportion of patients below the detection limit for Covid-19 on day three of treatment with pomotrelvir compared to a placebo.
In the pomotrelvir treated group, 70% of participants reached undetectable levels of virus, and 63% in the placebo group.
Pardes Biosciences chair and CEO Thomas Wiggans said: “We continue to believe in the need for new oral antivirals for Covid-19, and the importance of continued investment in next generation therapeutics that will be needed to help prevent the next pandemic.
“However, these unexpected results have forced us to make the difficult decision to suspend further development of pomotrelvir and pursue alternative strategic opportunities for the company.”
A total of 242 participants were enrolled at 63 sites within the US. The participants included adult patients aged 18 to 65 years with mild to moderate Covid-19 who are otherwise healthy, tested-positive, symptomatic, non-hospitalised, and vaccinated, but with no risk factors for developing severe illness.
The company stated that the otherwise healthy, vaccinated participants who have no risk factors for severe disease progression had quick virus clearance and alleviation of targeted as well as key Covid-19 symptoms independent of treatment.
Pomotrelvir was found to be well tolerated. No deaths were reported in the trial and no subjects experienced progression to severe disease.